Janet Kumita

Dr. Janet Kumita

Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in Nature
Verified
Journal Article
Closed access
PDF file
JJJae-Hoon Jung
Jae-Hoon Jung
ABAntonio D. Barbosa
Antonio D. Barbosa
SHStephanie Hutin
Stephanie Hutin
Janet KumitaJanet Kumita
Janet Kumita
MGMingjun Gao
Mingjun Gao
PWPhilip A. Wigge
Philip A. Wigge

15 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
Ryan LimbockerRyan Limbocker
Ryan Limbocker
Sean ChiaSean Chia
Sean Chia
FRFrancesco Simone Ruggeri
Francesco Simone Ruggeri
MPMichele Perni
Michele Perni
RCRoberta Cascella
Roberta Cascella
CDChristopher M. Dobson
Christopher M. Dobson
Transient oligomeric species formed during the aggregation process of the 42-residue form of the amyloid-β peptide (Aβ42) are key pathogenic agents in Alzheimer’s disease (AD). To investigate the relationship between Aβ42 aggregation and its cytotoxicity and the influence of a potential drug on both phenomena, we have studied the effects of trodusquemine. This aminosterol enhances the rate of aggregation by promoting monomer-dependent secondary nucleation, but significantly reduces the toxicity of the resulting oligomers to neuroblastoma cells by inhibiting their binding to the cellular membranes. When administered to a C. elegans model of AD, we again observe an increase in aggregate formation alongside the suppression of Aβ42-induced toxicity. In addition to oligomer displacement, the reduced toxicity could also point towards an increased rate of conversion of oligomers to less toxic fibrils. The ability of a small molecule to reduce the toxicity of oligomeric species represents a potential therapeutic strategy against AD.

28 June 2018 in ACS Chemical Biology
Verified
Journal Article
Closed access
MPMichele Perni
Michele Perni
PFPatrick Flagmeier
Patrick Flagmeier
Ryan LimbockerRyan Limbocker
Ryan Limbocker
RCRoberta Cascella
Roberta Cascella
FAFrancesco Antonio Aprile
Francesco Antonio Aprile
CDChristopher M. Dobson
Christopher M. Dobson

21 July 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
YCYiping Cao
Yiping Cao
JAJozef Adamcik
Jozef Adamcik
MDMichael Diener
Michael Diener
Janet KumitaJanet Kumita
Janet Kumita
RMRaffaele Mezzenga
Raffaele Mezzenga

11 March 2020 in ACS Nano
Verified
Journal Article
Closed access
FRFrancesco Simone Ruggeri
Francesco Simone Ruggeri
PFPatrick Flagmeier
Patrick Flagmeier
Janet KumitaJanet Kumita
Janet Kumita
GMGeorg Meisl
Georg Meisl
DCDimitri Y. Chirgadze
Dimitri Y. Chirgadze
CDChristopher M. Dobson
Christopher M. Dobson

13 August 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
RLRyan Limbocker
Ryan Limbocker
BMBenedetta Mannini
Benedetta Mannini
FRFrancesco Simone Ruggeri
Francesco Simone Ruggeri
RCRoberta Cascella
Roberta Cascella
CXCatherine K. Xu
Catherine K. Xu
CDChristopher M. Dobson
Christopher M. Dobson
The onset and progression of numerous protein misfolding diseases are associated with the presence of oligomers formed during the aberrant aggregation of several different proteins, including amyloid-β (Aβ) in Alzheimer’s disease and α-synuclein (αS) in Parkinson’s disease. These small, soluble aggregates are currently major targets for drug discovery. In this study, we show that trodusquemine, a naturally-occurring aminosterol, markedly reduces the cytotoxicity of αS, Aβ and HypF-N oligomers to human neuroblastoma cells by displacing the oligomers from cell membranes in the absence of any substantial morphological and structural changes to the oligomers. These results indicate that the reduced toxicity results from a mechanism that is common to oligomers from different proteins, shed light on the origin of the toxicity of the most deleterious species associated with protein aggregation and suggest that aminosterols have the therapeutically-relevant potential to protect cells from the oligomer-induced cytotoxicity associated with numerous protein misfolding diseases.